| | Publikationen |
|
Publikationen Greiner RA, Meier Y, Papadopoulos G, O’Sullivan A, Imhof A. Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland. European Journal of Cancer Care, submitted Wasserfallen JB, Krieg MA, Greiner RA, Lamy O. Cost effectiveness and cost-utility of risedronate for osteoporosis treatment and fracture prevention in women: a swiss perspective. Journal of Medical Economics, in press Brändle M, Azoulay M, Greiner RA. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2007; 45 (4): 203-220. Lippuner K, Golder M, Greiner RA. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporosis Int. 2005 Mar; 16 Suppl 2: 8-17. Epub 2004 Sep 16. Frei A, Greiner RA. Sparpotenzial: Eine Milliarde. Der volkswirtschaftliche Nutzen der Psychotherapie. Psychoscope 2001; 5: 14-18. ––– Frei A, Greiner RA. Economiser un milliard de francs. Une étude sur les avantages économiques de la psychothérapie. Psychoscope 2001; 22: 32-34 Ghatnekar O, Persson U, Willis M, Ödegaard K. Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. (Including data from Switzerland assessed by Greiner RA). Pharmacoeconomics 2001; 19 (7): 767-778 Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Seminars in Ophthalmology 2001; 26 (4): 218-222 Frei A, Greiner RA, Mehnert A, Dinkel R. Socioeconomic Evaluation of Heroin Maintenance Treatment. In: Gutzwiller F, Steffen T (eds). Cost-Benefit Analysis of Heroin Maintenance Treatment. Karger Basel 2000 Gianotti L, Braga M, Frei A, Greiner RA, Di Carlo V. Health care resources consumed to treat postoperative infections: cost saving by perioperative immunonutrition. Shock 2000; 14 (3): 325 30 Frei A, Greiner RA, Senkal M, Kemen M. Kostenanalyse der oralen und klinischen Ernährung im Krankenhaus. Akt. Ernähr.-Med. 24, 1999; 105-111 Frei A, Steffen T, Gasser M, Kümmerle U, Stierli M, Dobler-Mikola A, Gutzwiller F, Uchtenhagen A und Forschungsteam PROVE. Gesundheitsökonomische Bewertung der Versuche für eine ärztliche Verschreibung von Betäubungsmitteln (PROVE). Sozial und Präventivmedizin. Soz Präventivmed 1998; 43: 185-194 Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73 (7): 1339-1347 Greiner RA, Jacobs-Krahnen D, Mutzel R, Wurster B, Malchow D. A 138 kDa glycoprotein from Dictyostelium membranes with folate deaminase and folate binding activity. J Biol Chem 1992; 267 (8): 5096-5101 Greiner RA. Reindarstellung und Charakterisierung von Folsäurebindeprotein und Folsäuredeaminase aus der Zellmembran von Dictyostelium discoideum - Dissertation. Universität Konstanz. Hartung-Gorre Verlag Konstanz 1990
Greiner RA, Meier Y, O’Sullivan A, Imhof A. Cost-effectiveness of posaconazole versus standard azole therapy for the prevention of invasive fungal infections in high-risk patients in Switzerland. 34th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), March 30-April 2, 2008, Florence, Italy Greiner RA, Braathen L. Cost effectiveness of biologics for moderate to severe psoriasis from the perspective of the Swiss healthcare system. Poster P093, 2nd International Congress on Psoriasis, June 21-24, 2007, Paris, France Lamy O, Krieg MA, Wasserfallen JB, Greiner RA, Russ W. Cost-effectiveness of risedronate therapy in postmenopausal women with varying risk of osteoporotic fractures: A swiss analysis. Abstract submitted at 2nd Joint Meeting of the International Bone and Mineral Society (IBMS) and the European Society for Calcified Tissue (ECTS), June 25-29, 2005, Geneva, Switzerland Lamy O, Krieg MA, Wasserfallen JB, Greiner RA, Russ W. Cost-effectiveness of risedronate in patients at high risk for osteoporotic fractures in Switzerland. Abstract accepted at Fifth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO5), POSTER P282, March 16-19, 2005, Rome, Italy Brändle M, Russ W, Greiner RA. Cost-effectiveness analysis of insulin glargine (Lantus®) compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes mellitus Model in patients with Type 2 diabetes in Switzerland. Poster presentation at 40th Annual Meeting of the European Association for the Study of Diabetes (EASD), September 5-9, 2004, Munich, Germany Lippuner K, Greiner RA. Incidence and direct medical costs of hospitaliations due to osteoporotic fractures in Switzerland in the year 2000. Poster presentation at Fourth European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ECCEO 4), Nice, France, November 14-17, 2003 Frei A, Greiner RA, Mehnert A, Dinkel R. Socioeconomic evaluation of the Heroin-assisted treatment for dependent drug users in Switzerland. International symposium, Bern, March 10-12, 1999 Rülicke T, Speiser DE, Greiner RA, Kyburz D, Autenried P, Zinkernagel RM. Thymusdifferenzierung in nu/nu-scid/scid Maus Aggregationschimären. J Soc Lab Animal Science; 28. Wissenschaftliche Tagung der Gesellschaft für Ver¬suchstierkunde, Lübeck, 9.-13.9.1991 Greiner RA, Jacobs-Krahnen D, Mutzel R, Lichtenberg B, Wurster B, Malchow D. Isolation and characterization of folate deaminase and a folate binding-protein from the cell surface of Dictyostelium discoideum. Joint autumn meeting of the Austrian Biochemical Society and the Society for Biological Chemistry. 12-14 September 1988, Innsbruck. Biological Chemistry Hoppe-Seyler 1988; 369: 825 |